Filter By Category
Archives
Share on -
AVELUMAB
Generic Name: AVELUMAB
ABSTRACT -
Avelumab is a human IgG1 monoclonal antibody that blocks programmed death ligand 1 (PD-L1) and is used where approved as an anticancer immunotherapy. It is a biologic antibody and does not have a single small-molecule skeletal structure. The representation above is an antibody schematic.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- Use only according to the approved local product label and institutional administration procedures.
- Infusion or injection settings must have monitoring and emergency support as required for the product class.
- Do not administer outside authorized indications or specialist supervision.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Fatigue, nausea, diarrhea, decreased appetite, rash, or pruritus
- Infusion-related reactions including chills, fever, flushing, or hypotension
- Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, or skin reactions
- Infections or laboratory abnormalities may occur
- Severe immune-mediated reactions can be life-threatening
ALLERGIC REACTIONS -
Hypersensitivity to Avelumab or related compounds/products may occur. Symptoms may include:
- Immediate urticaria, itching, flushing, or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, or breathing difficulty
- Dizziness, fainting, severe hypotension, or collapse
- Anaphylaxis, although uncommon, requires emergency medical treatment
Important: Patients who develop an allergic reaction to Avelumab should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Avelumab may interact with certain medicines, biologics, vaccines, protocols, or clinical conditions. Caution is needed with:
- Systemic immunosuppressants may reduce antitumor immune activity but may be needed for toxicity management.
- Other immune checkpoint inhibitors or immunostimulants can increase immune-toxicity risk.
- Live vaccines require oncology guidance.
- Patients should report all medicines, supplements, and vaccines.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Monitor for new cough, diarrhea, abdominal pain, jaundice, severe rash, endocrine symptoms, or neurologic changes.
- Manage infusion reactions with appropriate premedication and monitoring as directed.
- Use caution in autoimmune disease or transplant history.
- Pregnancy and lactation require oncology risk-benefit review.
WARNINGS –
- Immune-mediated adverse reactions can occur at any time and require prompt evaluation.
- Severe infusion reactions require interruption or discontinuation according to label.
- Use only under oncology supervision.
- Keep out of reach of children.
Share on -
. Developed by